At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
Pioglitazonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas
University of Texas Southwestern Medical Center·interventional·Posted Apr 24, 2013·Updated Mar 1, 2021
In Brief
A Phase 2 clinical trial evaluating Pioglitazone for Cancer of the Pancreas. Completed, enrolled 14 participants across 1 site.
Detailed Summary
This study is being done to determine whether or not addition of the oral medication, pioglitazone to standard chemotherapy, results in improvement of blood tests that measure the body's ability to utilize sugar (glucose and insulin metabolism). In addition the investigators want to determine whether or not treatment with pioglitazone results in (1) improvement in the size of the tumor, (2) weight gain, (3) improved ability to function during the day and (4) quality of life.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer of the Pancreas
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartMay 2013
Primary CompletionSep 2017
TodayJul 2026
First PostedApr 24, 2013
Enrollment StartMay 1, 2013
Primary CompletionSep 20, 2017
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 13.2 years ago
Interventions
Pioglitazonedrug